Baseret på data, der er fremskaffet under kliniske forsøg med Naglazyme, forventes størstedelen af patienterne at udvikle IgG antistoffer over for galsulfase inden for 4- 8 uger efter behandlingens start.
Based on data obtained during Naglazyme clinical trials, the majority of patients are expected to develop IgG antibodies to galsulfase within 4-8 weeks of treatment initiation.